Resources


October 2, 2020

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

- Project Focused on Proteins used in the Production of Blood Cells -

Continue Reading

September 9, 2020

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies –

Continue Reading

August 10, 2020

iBio Provides Update on IBIO-201 COVID-19 Vaccine Program

IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract ...

Continue Reading

June 24, 2020

TEXAS A&M TESTS COVID-19 VACCINE CANDIDATES FOR IBIO, INC.

by tamus | Jun 24, 2020 | System News       Chancellor Sharp praises partnership between university, biotech firm   COLLEGE STATION, Texas — A team of scientists at Texas A&M is working on two COVID-19 vaccine candidates that could be mass produced ...

Continue Reading

June 24, 2020

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology ...

Continue Reading
1 2 3